Oneoncology — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$803,246	70
2024	Research	$508,876	39
2023	Research	$654,339	15

Breakdown

Who paid Research payments · program years 2023–2025

AstraZeneca Pharmaceuticals LP $1,087,749 37 payments
Celgene Corporation $587,055 11 payments
GlaxoSmithKline, LLC. $184,056 70 payments
E.R. Squibb & Sons, L.L.C. $103,828 3 payments
Mirati Therapeutics, Inc. $3,772 3 payments

Studies the money was for Research payments · program years 2023–2025

Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) $557,625 25 payments
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) $430,224 6 payments
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge $215,762 3 payments
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and or Refractory Multiple Myeloma. $169,820 2 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) $133,025 2 payments
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M $103,600 44 payments
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evalua $75,867 24 payments
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) $65,401 1 payment
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) $57,000 3 payments
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). $44,750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.